Antisense Therapeutics Scientist Out To Pull More Big Deals

Aiming for more major licensing deals like the one his company recently secured with top 20 global pharmaceutical company, Teva, is front of mind for rising Australian biotechnology star, Antisense Therapeutics Ltd (ASX code: ANP)Research Director Dr Christopher Wraight when he meets with leading industry figures in the US in May.

More: continued here

Filed under: Pharma Industry on April 2nd, 2008